Ultragenyx Pharmaceutical Inc. (RARE) Company Profile & Statistics

Ultragenyx Pharmaceutical Inc.
RARE
(Nasdaq - US)
N/A
44.83
-0.23 (-0.51%)
in:usd•As of: Jul 26, 2024 15:59 UTC -4
Open
45.75
High
45.79
Low
44.43

About Ultragenyx Pharmaceutical Inc.

CEO

Emil D. Kakkis

Headquarters

60 leveroni court

novato, ca 94949, united states

Auditor

Ernst & Young LLP

Employees

1,276

Share Holders

Website

www.ultragenyx.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

Ultragenyx Pharmaceutical Inc. Statistics

Valuation Measures

Market Capitalization ²	3.73B
Enterprise Value	3.61B
Enterprise Value/EBITDA (ttm)	-6.40
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	26.74
Price to Sales (ttm)	8.47
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	88.52%
Operating Margin (ttm)	-138.58%
Profit Margin (ttm)	-140.98%
Return on Equity (ttm)	-425.63%
Return on Invested Capital (ttm)	-793.69%
Return on Assets (ttm)	-45.88%

Income Statement

Revenue (ttm)	442.59M
Revenue Per Share (ttm)	5.32
Gross Profit (ttm)	392.10M
EBITDA (ttm)³	-564.44M
Net Income Avi to Common (ttm)	-613.35M
Diluted EPS (ttm)	-8.03

Share Statistics

Beta (5Y Monthly)	0.56
52-Week Change	6.38%
S&P500 52-Week Change	19.54%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	83.13M
Dividend Yield	0.00%
Float ⁴	78.31M
% Held by Insiders	5.80%
% Held by Institutions	97.67%

Balance Sheet

Total Cash (mrq)	412.08M
Total Cash Per Share (mrq)	4.96
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	2.43%
Quick Ratio (mrq)	2.28%
Book Value Per Share (mrq)	1.69

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.26
Free Cash Flow (ytd)	-193.94M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Ultragenyx Pharmaceutical Inc.

Trade With A Regulated Broker